Positron Emission Tomography (PET) study with [11C]AZD2995 and [11C]AZD2184, candidate PET ligands for β amyloid - PET
Study identifier:D0180C00018
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Open label Positron Emission Tomography (PET) study with [11C]AZD2995 and [11C]AZD2184, candidate PET ligands for β amyloid, to determine and compare in vivo brain uptake and distribution in healthy volunteers and patients with Alzheimer’s Disease
Medical condition
Alzheimer´s disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
Radioligand (11C)AZD2995, Radioligand (11C)AZD2184
Sex
All
Actual Enrollment
13
Study type
Interventional
Age
20 Years - 85 Years
Date
Study Start Date: 01 Jan 2008
Primary Completion Date: 01 Dec 2008
Study Completion Date: 01 Dec 2008
Study design
Allocation: Non-randomized
Endpoint Classification: N/A
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Jan 2009 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Other: 1 Alzheimer's Disease (AD) patients | Drug: Radioligand (11C)AZD2995 Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers. Drug: Radioligand (11C)AZD2184 Single dose of i.v solution. Once for AD patients respective healthy volunteers. |
| Other: 2 Healthy volunteers | Drug: Radioligand (11C)AZD2995 Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers. Drug: Radioligand (11C)AZD2184 Single dose of i.v solution. Once for AD patients respective healthy volunteers. |
Contacts
Investigators
Principal Investigator
Maria E Jönhagen
Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden
